Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Nursing Considerations for Patients Treated with Targeted Therapies

  • Chapter
  • First Online:
Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners

  • 530 Accesses

Abstract

Delivery of personalized, effective therapy to patients with metastatic lung cancer with an identified driver mutation can be challenging and rewarding. Nurses can make significant impacts in the management of these complex patients through access to therapy, education, telephone triage, interventions to improve adherence and persistence, and care coordination/navigation. A multidisciplinary team approach may improve patient quality of life and survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 59.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Cancer Society. Cancer facts and figures 2019. Atlanta: American Cancer Society; 2019.

    Google Scholar 

  2. Farago A, Azzoli CG. Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer. Transl Lung Cancer Res. 2017;6(5):550–9.

    Article  CAS  Google Scholar 

  3. Tipton JM. Overview of the challenges related to oral agents for cancer and their impact on adherence. Clin J Oncol Nurs. 2015;19(3):37–40.

    Article  Google Scholar 

  4. Hicks KM, Cope D, Novak J, Scherer S. The role of the advanced practitioner in maintaining adherence in patients on oral oncolytics. J Adv Pract Oncol. 2017;8(6):7–21.

    Google Scholar 

  5. Stein J, Mann J. Specialty pharmacy services for patients receiving oral medications for solid tumors. Am J Health Syst Pharm. 2016;73(11):775–96.

    Article  CAS  Google Scholar 

  6. Stokes M, Reyes C, Xia Y, Alas V, Goertz HP, Boulanger L. Impact of pharmacy channel on adherence to oral oncolytics. BMC Health Serv Res. 2017;17(1):414.

    Article  Google Scholar 

  7. Agarwal A, Freedman R, Goicuria F, Rhinehart C, Murphy K, Kelly E, et al. Prior authorization for medications in breast oncology: navigation of a complex problem. J Oncol Pract. 2017;13(4):e273–82. https://doi.org/10.1200/JOP.2016.017756.

    Article  PubMed  Google Scholar 

  8. Anders B, Shillingburg A, Newton M. Oral antineoplastic agents: assessing the delay in care. Chemother Res Pract. 2015;2015:512016, 4 pages. https://doi.org/10.1155/2015/512016.

    Article  Google Scholar 

  9. Bach PB. Monthly and median costs of cancer drugs at the time of FDA approval 1965–2016. J Natl Cancer Inst. 109(8). https://doi.org/10.1093/jnci/djx173.

  10. Dusetzina SB. Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans. JAMA Oncol. 2016;2(7):960–1.

    Article  Google Scholar 

  11. Olszewski AJ, Zullo AR, Nering CR, Huynh JP. Use of charity financial assistance for novel oral anticancer agents. J Oncol Pract. 2018;14(4):e221–8.

    Article  Google Scholar 

  12. Egerton NJ. In-office dispensing of oral oncolytics: a continuity of care and cost mitigation model for cancer patients. Am J Manag Care. 2016;22(4 Suppl):s99–s103.

    PubMed  Google Scholar 

  13. Dusetzina SB, Huskamp HA, Winn AN, Basch E, Keating NL. Out-of-pocket and health care spending changes for patients using orally administered anticancer therapy after adoption of state parity laws. JAMA Oncol. 2018;4:e173598.

    Article  Google Scholar 

  14. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378:113–25.

    Article  CAS  Google Scholar 

  15. Astra-Zeneca. US FDA approves Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer. 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm605113.htm. Accessed 15 Dec.

  16. Cordova MJ, Riba MB, Spiegel D. Post-traumatic stress-disorder and cancer. Lancet Psychiatry. 2017;4:330–8.

    Article  Google Scholar 

  17. Apor E, Connell NT, Faricy-Anderson K, et al. Prechemotherapy education: reducing patient anxiety through nurse-led teaching sessions. Clin J Oncol Nurs. 2018;22(1):76–81.

    Article  Google Scholar 

  18. Wittenberg E, Ferrell B, Kanter E, Buller H. Health literacy: exploring nursing challenges to providing support and understanding. Clin J Oncol Nurs. 2018;22(1):53–61.

    Article  Google Scholar 

  19. Loerzel VW. Symptom self-management: strategies use by older adults receiving treatment for cancer. Clin J Oncol Nurs. 2018;22(1):83–90.

    Article  Google Scholar 

  20. Boucher J, Lucca J, Hooper C, Pedulla L, Berry DL. A structured nursing intervention to address oral chemotherapy adherence in patients with non-small cell lung cancer. Oncol Nurs Forum. 2015;42(4):383–9.

    Article  Google Scholar 

  21. Lemonade M. MASCC Oral Agent Teaching Tool (MOATT): yesterday, today and tomorrow. Can Oncol Nurs J. 2014;24(3):207–10.

    Google Scholar 

  22. Rittenberg CN. Meeting educational needs and enhancing adherence of patients receiving oral cancer agents through use of the MASCC Oral Agent Teaching Tool©. Eur Oncol Haematol. 2012;8(2):97–100.

    Article  Google Scholar 

  23. Melosky B, Hirsh V. Management of common toxicities in metastatic NSCLC related to anti-lung cancer therapies with EGFR-TKIs. Front Oncol. 2014;4:238. https://doi.org/10.3389/fonc.2014.00238.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstien JB, Eaby-Sandy B, Murphy BA, MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079–95.

    Article  Google Scholar 

  25. Matthews J, Caprera PH. Essentials of oral oncolytics: developing a nursing reference. Clin J Oncol Nurs. 2014;18(5):e88–91. https://doi.org/10.1188/14.cjon.e88-e92.

    Article  PubMed  Google Scholar 

  26. Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, et al. First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study. JAMA Oncol. 2016;2(3):305–12. https://doi.org/10.1001/jamaoncol.2015.4921.

    Article  PubMed  Google Scholar 

  27. Na F, Zhang J, Deng L, Zhou X, Zhou L, Zou B, et al. Continuation of tyrosine kinase inhibitor is associated with survival benefit in NSCLC patients with exon 19 deletion after solitary brain progression. J Cancer. 2017;8(18):3682–8. https://doi.org/10.7150/jca.20017.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Gleason K, O’Neill EB, Goldschmitt J, Horigan J, Moriarty L. Ambulatory oncology nurses making the right call: assessment and education in telephone triage practices. Clin J Oncol Nurs. 2013;17(3):335–6. https://doi.org/10.1188/13.cjon.335-336.

    Article  PubMed  Google Scholar 

  29. Hunis B, Alencar AJ, Castrellon AB, et al. Making steps to decrease emergency room visits in patients with cancer: our experience after participating in the ASCO Quality Training Program. 2016 ASCO Quality Care Symposium. Presented February 26, 2016. http://www.ascopost.com/issues/march-25-2016/phone-triage-system-offers-potential-to-reduce-patient-visits-to-the-emergency-department-for-cancer-treatment-related-symptoms. Accessed 2 Dec 2017.

  30. Flanner M, Philips SM, Lyons CA. Examining telephone calls in ambulatory oncology. J Oncol Pract. 2009;5(2):57–60. https://doi.org/10.1200/JOP.0922002.

    Article  Google Scholar 

  31. Stacey D, Bakker D, Ballantyne B, Chapman K, Cumminger J, Green E, et al. Managing symptoms during cancer treatments: evaluating the implementation of evidence-informed remote access protocols. Implement Sci. 2012;19(7):110. https://doi.org/10.1186/1748-5908-7-110.

    Article  Google Scholar 

  32. Telephone triage for oncology nurses. 2nd ed. In: Hickey M, Newton S, editors. Pittsburgh, PA: Oncology Nursing Society; 2012.

    Google Scholar 

  33. Oncology Nursing Society. Tools for oral adherence toolkit [pamphlet]. Pittsburgh, PA: Oncology Nursing Society; 2009. https://www.ons.org/sites/default/files/oral%20adherence%20toolkit.pdf.

  34. Atkinson TM, Rodriguez VM, Gordon M, Avildsen IK, Emanu JC, Jewell ST, Anselmi KA, Ginex PK. The association between patient-reported and objective oral anticancer medication adherence measures: a systematic review. Oncol Nurs Forum. 2016;43:576–82.

    Article  Google Scholar 

  35. Winkeljohn D. Adherence to oral cancer therapies: nursing interventions. Clin J Oncol Nurs. 2015;14(4):461–6.

    Article  Google Scholar 

  36. Barillet M, Prevost V, Joly F, Clarisse B. Oral antineoplastic agents: how do we care about adherence? Br J Clin Pharmacol. 2015;80(6):1289–302. https://doi.org/10.1111/bcp.12734.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Wickersham K, Beth M, Bender CM, Engberg SJ, Tarhini A, Erlen JA. Surviving with lung cancer: medication-taking and oral targeted therapy. Geriatr Nurs. 2014;35(2):S49–56. https://doi.org/10.1016/j.gerinurse.2014.02.020.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521–30.

    Article  Google Scholar 

  39. Goren A, diBonaventura M, Wagner R. Adherence and its association with health outcomes among patients currently treated for leukemia, melanoma, or non-small cell lung cancer. Value Health. 2013;16(3):A144.

    Article  Google Scholar 

  40. Timmers L, Boons CC, Moes-Ten Hove J, Smit EF, van de Ven PM, Aerts JG, et al. Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer. J Cancer Res Clin Oncol. 2015;141(8):1481–91. https://doi.org/10.1007/s00432-015-1935-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Gebbia V, Bellavia M, Banna GL, Russo P, Ferrau F, Tralongo P. Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer. Clin Lung Cancer. 2013;14(4):390–8. https://doi.org/10.1016/j.cllc.2012.11.007.

    Article  CAS  PubMed  Google Scholar 

  42. Lucca JV, Hooper CL, Boucher J, Pedulla LV, Berry DL, Marcoux JP. A pilot study of direct care nurse (DCN) education to improve adherence and knowledge of erlotinib in patients with non-small cell lung cancer. J Clin Oncol. 2012;30(Suppl):e19637. https://doi.org/10.1200/jco.2012.30.15_suppl.e.019637.

    Article  Google Scholar 

  43. Hess LM, Louder A, Winfree K, Zhu YE, Oton AB, Nair R. Factors associated with adherence to and treatment duration of erlotinib among patients with non-small cell lung cancer. J Manag Care Spec Pharm. 2017;23(6):643–52. https://doi.org/10.18553/jmcp.2017.16389.

    Article  PubMed  Google Scholar 

  44. Berry DL, Blonquist TM, Hong F, Halpenny B, Partridge AH. Self-reported adherence to oral cancer therapy: relationships with system distress, depression, and personal characteristics. Patient Prefer Adherence. 2015;9:1587–92. https://doi.org/10.2147/ppa.s91534.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Given BA, Given CW, Sikorskii A, Vachon E, Banik A. Medication burden of treatment using oral cancer medications. Asia Pac J Oncol Nurs. 2017;4(4):275–82. https://doi.org/10.4103/apjon.apjon_7_7.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Dowling M, Hunter A, Biesty L, Meskell P, Conway A, O’Boyle G, Morrissey E, Houghton C. Driving and disabling factors of noncurative oral chemotherapy adherence: a qualitative evidence synthesis. Oncol Nurs Forum. 2019;46(1):16–28.

    PubMed  Google Scholar 

  47. Jacobs JM, Pensak NA, Sporn NJ, MacDonald JJ, Lennes IT, Safren SA, et al. Treatment satisfaction and adherence to oral chemotherapy in patients with cancer. J Oncol Pract. 2017;13(5):e474–85. https://doi.org/10.1200/JOP.2016.019729.

    Article  PubMed  Google Scholar 

  48. Foulon V, Schoffski P, Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg. 2011;66(2):85–96. https://doi.org/10.2143/acb.66.2.2062525.

    Article  CAS  PubMed  Google Scholar 

  49. Spoelstra SL, Rittenberg CN. Assessment and measurement of medication adherence: oral agents for cancer. Clin J Oncol Nurs. 2015;19(3):47–52.

    Article  Google Scholar 

  50. Spoelstra SL, Sikorskii A, Majumder A, Burhenn PS, Schueller M, Given B. Oral anticancer agents: an intervention to promote medication adherence and symptom management. Clin J Oncol Nurs. 2017;21(2):157–60.

    Article  Google Scholar 

  51. Mathes T, Antoine SL, Pieper D, Eikermann M. Adherence enhancing interventions for oral anticancer agents: a systematic review. Cancer Treat Rev. 2014;40(1):102–8. https://doi.org/10.1016/j.ctrv.2013.07.004.

    Article  PubMed  Google Scholar 

  52. Burhenn PS, Smuddle J. Using tools and technology to promote education and adherence to oral agents for cancer. Clin J Oncol Nurs. 2015;19(3):53.

    Article  Google Scholar 

  53. Wu YP, Linder LA, Kanokvimankul P, Fowler B, Parsons BG, Mcpherson CF, Johnson RH. Use of smartphone application for prompting oral medication adherence among adolescents and young adults with cancer. Oncol Nurs Forum. 2018;45(1):69–77.

    Article  Google Scholar 

  54. Ellis PM. The importance of multidisciplinary team management of patients with non-small-cell lung cancer. Curr Oncol. 2012;19(S1):S7–15. https://doi.org/10.3747/co.19.1069.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Pan C-C, Kung P-T, Wang Y-H, Chang Y-C, Shih-Ting W, Tsai W-C. Effects of multidisciplinary team care on the survival of patients with different stages of non-small cell lung cancer: a national cohort study. PLoS One. 2015;10(5):e0126547. https://doi.org/10.1371/journal.pone.0126547.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Pezzuto A, Terzo F, Graziani ML, Ricci A, Bruno P, Mariotta S. Lung cancer requires multidisciplinary treatment to improve patient survival: a case report. Oncol Lett. 2017;14(3):3035–8. https://doi.org/10.3892/ol.2017.6511.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Kim C, Roper N, Hoang CD, Szabo E, Connolly M, Padiernos E. Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib. J Clin Oncol. 2017;35(S15):e20545. https://doi.org/10.1200/jco.2017.35.15_suppl.e20545.

    Article  Google Scholar 

  58. Bade BC, Silvestri GA, Ford DE. Providing palliative care for patients with lung cancer. Clin Pulm Med. 2017;24(3):105–11. https://doi.org/10.1097/cpm.0000000000000203.

    Article  Google Scholar 

  59. Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, et al. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014;15(1):1–6. https://doi.org/10.1016/j.cllc.2013.10.001.

    Article  CAS  PubMed  Google Scholar 

  60. Yap TA, Macklin-Doherty A, Popat S. Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. Eur J Cancer. 2016;70:12–21. https://doi.org/10.1016/j.ejca.2016.10.014.

    Article  CAS  PubMed  Google Scholar 

  61. Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(3):346–51.

    Article  CAS  Google Scholar 

  62. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807–14.

    Article  CAS  Google Scholar 

  63. Inomata M, Shukya T, Takahashi T, Ono A, Nakamura Y, Tsuya A, et al. Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer. Anticancer Res. 2011;31(12):4519–23.

    PubMed  Google Scholar 

  64. Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer. 2005;103(11):2344–8.

    Article  CAS  Google Scholar 

  65. Heon S, Yeap BY, Britt CJ, Csta DB, Rabin MS, Jackman DM, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010;16(23):5873–82.

    Article  CAS  Google Scholar 

  66. Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT. The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2013;8(12):1570–3. https://doi.org/10.1097/jto.000000000000029.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Thoracic Cancers Team, Massachusetts General Hospital Cancer Center, Boston, MA, USA

    Kelly E. Goodwin

  2. Yale Comprehensive Cancer Center, Yale University School of Nursing, New Haven, CT, USA

    Marianne Davies

Authors
  1. Kelly E. Goodwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marianne Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marianne Davies .

Editor information

Editors and Affiliations

  1. Yale Comprehensive Cancer Center, Yale University School of Nursing, New Haven, CT, USA

    Marianne Davies

  2. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

    Beth Eaby-Sandy

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Goodwin, K.E., Davies, M. (2019). Nursing Considerations for Patients Treated with Targeted Therapies. In: Davies, M., Eaby-Sandy, B. (eds) Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. Springer, Cham. https://doi.org/10.1007/978-3-030-16550-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16550-5_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16549-9

  • Online ISBN: 978-3-030-16550-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation